Ultragenyx Pharmaceutical Inc. (RARE): Results of Operations and Financial Condition
Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update Second quarter total reven
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 revenue trajectory and model probability-weighted outcomes for multiple late-2026 FDA and Phase 3 catalysts.
Market read
The filing combines quantified financial guidance with a dated catalyst schedule, which can reprice near-term risk and event-driven trading setups.
What to watch
Cash burn remains substantial (net cash used in operations $97M in Q2), so any delay or adverse regulatory/clinical outcome could outweigh near-term guidance confidence.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Q2 2026 financial results and a corporate update for Ultragenyx.
Ticker impact
Ultragenyx reported Q2 2026 results and reaffirmed 2026 revenue guidance, while flagging upcoming PDUFA dates and GTX-102 Phase 3 data timing.
Likely positive bias with event-driven swings around Aug 23 and Sep 19 PDUFAs and the Sep-Oct GTX-102 data window.
The filing provides concrete financial guidance ranges, cash balance, and specific regulatory/clinical milestones with expected timing, which are direct inputs to risk/reward for the stock.
Market effects
Reinforces investor focus on gene therapy and rare-disease biotech catalyst calendars tied to PDUFA and pivotal readouts.
Limited direct regional spillover; Japan launch and NHI listing may support incremental demand narrative.
Moderate global relevance via FDA review timelines and multinational commercialization updates.
Counterpoint
Reaffirmed guidance may be viewed as maintenance rather than upside, and the largest value inflection (GTX-102 Phase 3) is still pending.
Key entities
- issuerUltragenyx Pharmaceutical Inc.
Reported Q2 2026 financial results, reaffirmed 2026 guidance, and outlined upcoming regulatory and clinical milestones.
- productCrysvita
Reported Q2 2026 revenue of $156M and reaffirmed 2026 guidance of $500M to $520M.
- productDojolvi
Reported Q2 2026 revenue of $27M and reaffirmed 2026 guidance of $100M to $110M, with Japan launch and NHI listing noted.
- clinical_programDTX401
FDA accepted BLA for review with PDUFA action date of Aug 23, 2026.
- clinical_programUX111
FDA accepted resubmitted BLA for accelerated approval with PDUFA action date of Sep 19, 2026.
